BMYMP:OTC-Bristol-Myers Squibb Company PFD CONV 2 (USD)

COMMON STOCK | Other | OTC

Last Closing Price

USD 1,055.00

Change

0.00 (0.00)%

Market Cap

USD 1,846.56B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-28 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SSNLF Samsung Electronics Co., Ltd

N/A

USD15,011.80B 9.00 N/A
DISPF Disco Corporation

N/A

USD3,369.71B 18.60 -488.90
CHKDJ Chesapeake Energy Corporation ..

N/A

USD1,315.84B N/A N/A
BAMKL Bank of America Corporation

N/A

USD267.26B 9.28 N/A
JGSMY JG Summit Holdings, Inc

-1.24 (-4.76%)

USD186.74B 30.58 0.22
UNLNF Unilever N.V

N/A

USD158.01B 24.49 N/A
LLOBF Lloyds Banking Group plc 9.25%..

N/A

USD134.80B N/A N/A
BPHLY Bank of the Philippine Islands

N/A

USD131.92B 12.00 N/A
RLLCF Rolls-Royce Holdings plc

N/A

USD106.82B N/A N/A
AZSEY Allianz SE

N/A

USD103.32B 11.82 N/A

ETFs Containing BMYMP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.46% N/A N/A N/A N/A
Dividend Return 0.09% N/A N/A N/A N/A
Total Return -7.37% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 12.38% N/A N/A N/A N/A
Dividend Return 0.16% N/A N/A N/A N/A
Total Return 12.54% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -3.59% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.59% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.02% N/A N/A N/A N/A
Dividend Return 0.16% N/A N/A N/A N/A
Total Return 0.13% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.36% N/A N/A N/A N/A
Risk Adjusted Return 0.72% N/A N/A N/A N/A
Market Capitalization 1,846.56B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3,555.56 N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 228.90 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 9.88% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 84.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.28 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike